Baidu
map

JAMA:降血压治疗2型糖尿病与延长生存期相关

2015-02-12 崔倩译 MedSci原创

根据JAMA 2月10日发表的一项研究,对糖尿病患者进行降血压治疗可降低心血管疾病(CVD)、心脏病以及死亡率升高的风险。 预计到2030年,全世界将有400万人患有2型糖尿病。2型糖尿病基本上会伴随着增加心脏病和中风的风险。在糖尿病患者中血压水平平均偏高,血压增高对糖尿病患者来说是一个公认的危险因素。根据文章中的背景信息,降低糖尿病患者的血压在目前看来存在争论性的,特别是在谁应该接受治疗和要达

根据JAMA 2月10日发表的一项研究,对糖尿病患者进行降血压治疗可降低心血管疾病(CVD)、心脏病以及死亡率升高的风险。

预计到2030年,全世界将有400万人患有2型糖尿病。2型糖尿病基本上会伴随着增加心脏病和中风的风险。在糖尿病患者中血压水平平均偏高,血压增高对糖尿病患者来说是一个公认的危险因素。根据文章中的背景信息,降低糖尿病患者的血压在目前看来存在争论性的,特别是在谁应该接受治疗和要达到的血压水平存在争论。

英国牛津大学乔治全球健康研究所的Kazem Rahimi和同事们进行了一次大型随机降血压对照试验的回顾和荟萃分析,其中也包括糖尿病患者,研究结果在1966年1月到2014年10月期间发表。根据搜索的医学文献,确定了40个试验被认为有低风险倾向(100354名参与者),并纳入分析降压治疗与2型糖尿病患者的血管疾病之间的关系。

研究人员发现,每降低10毫米汞柱血压就与死亡风险降低,心血管疾病,冠心病,中风,蛋白尿(尿中过多的蛋白质的存在)以及视网膜病变(糖尿病引发的失明)相关。在不考虑使用药物的情况下,除了中风和心脏衰竭,降压治疗和治疗结果之间没有显著不同。

虽然对低于心脏收缩血压水平140毫米汞柱的降血压水平进行了研究,数据表明,进一步减少至130毫米汞柱以下时,仍然较低风险的中风、视网膜病变和蛋白尿相关,这可能导致在这些结果的高风险下许多人是受益的。

作者写道“在2型糖尿病患者中,血压降低和降低死亡率及其他相关的临床结果相关。这些结果支持了这些患者使用降压药。”

评论:糖尿病患者的高血压治疗

伦敦大学学院的医学博士布莱恩威廉姆斯在一篇社论中写到:“这些发现是及时的,明确的,重要的,并且当2型糖尿病患者的收缩压为140毫米汞柱或更高时,能够为指导目前2型糖尿病患者的提供降压治疗的建议,目标收缩压为130毫米汞柱,但通常不会比这个更低。”

“然而, Emdin等人的研究结果表明,对于一些患者,这些治疗的阈值和目标可能过于保守,特别是用于减少中风和蛋白尿的发展或进展的风险。这个问题突出的难题是临床医生过度依赖于指南,而指南过度依赖于一种常态,不加鉴别的采取一些证据,尽管临床试验具有局限性。指南仅仅是基于群体为基础的保守性建议,所以医生必须能够解读语境中个别患者。”

原始出处

Bryan Williams. Treating Hypertension in Patients With Diabetes. JAMA, 2015; 313 (6): 573 DOI: 10.1001/jama.2015.89

Connor A. Emdin, Kazem Rahimi, Bruce Neal, Thomas Callender, Vlado Perkovic, Anushka Patel. Blood Pressure Lowering in Type 2 Diabetes. JAMA, 2015; 313 (6): 603 DOI: 10.1001/jama.2014.18574

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=20383, encodeId=66412038333, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:46:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16688, encodeId=e4f71668829, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15998, encodeId=2949159989d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:24:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15723, encodeId=1b2515e2345, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:52:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 14 00:36:00 CST 2015, time=2015-02-14, status=1, ipAttribution=)]
    2015-04-11 x35042875

    AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=20383, encodeId=66412038333, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:46:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16688, encodeId=e4f71668829, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15998, encodeId=2949159989d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:24:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15723, encodeId=1b2515e2345, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:52:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 14 00:36:00 CST 2015, time=2015-02-14, status=1, ipAttribution=)]
    2015-02-22 orthoW

    不错的文章,学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=20383, encodeId=66412038333, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:46:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16688, encodeId=e4f71668829, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15998, encodeId=2949159989d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:24:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15723, encodeId=1b2515e2345, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:52:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 14 00:36:00 CST 2015, time=2015-02-14, status=1, ipAttribution=)]
    2015-02-16 Johnny1989

    谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=20383, encodeId=66412038333, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:46:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16688, encodeId=e4f71668829, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15998, encodeId=2949159989d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:24:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15723, encodeId=1b2515e2345, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:52:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 14 00:36:00 CST 2015, time=2015-02-14, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    以阅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=20383, encodeId=66412038333, content=AKI对心衰临床治疗意义重大,但依然需要研究检验其适用性, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 22:46:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16688, encodeId=e4f71668829, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15998, encodeId=2949159989d, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:24:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15723, encodeId=1b2515e2345, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:52:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378063, encodeId=18e113e8063d2, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Feb 14 00:36:00 CST 2015, time=2015-02-14, status=1, ipAttribution=)]

相关资讯

MCP:中科院科学家揭示蛋白质丙二酰化修饰与2型糖尿病的相关性

随着人们生活水平的提高,糖尿病已经成为所有人不得不正视的问题。然而,经过这么多年的研究,科学家尚未能彻底了解清楚糖尿病的完整机理。 2015年1月1日,中科院杨福愉、杨福全等人发布在Molecular & Cellular Proteomics发表了题为“Lysine malonylation is elevated in type 2 diabetic mouse models and

JAMA:二甲双胍在2型糖尿病和肾脏疾病中的应用

普遍认为,二甲双胍是首选的治疗2型糖尿病的口服降糖药物。但是,由于其有导致乳酸酸中毒的风险,一直禁用于合并严重肾脏疾病的糖尿病患者。最近发表在JAMA上一篇文章,系统的评价合并严重肾脏疾病的糖尿病患者使用二甲双胍,出现乳酸酸中毒的风险。文章搜索了MEDLINE和 Cochrane两个数据库中,从1950年到2014年6月,所有关于二甲双胍,肾脏疾病,乳酸酸中毒的英文文献。排除了综述、快报、评论、案

FDA批准2型糖尿病的新组合药片Glyxambi

美国食品药品监督管理局已经批准empagliflozin / linagliptin组合药Glyxambi(勃林格殷格翰/礼来)作为成人2型糖尿病患者饮食和锻炼的辅助治疗。 该组合药剂在美国是首个将钠葡萄糖协同转运2(SGLT2)抑制剂(empagliflozin)与二肽基酶-4(DPP-4)抑制剂(linagliptin)进行组合每日一次服用的药片。该药片包含10毫克或者25毫克的empagl

Lancet Diab & Endo:2型糖尿病患者应注意心血管疾病风险!

流行病学研究表明,肥胖、高热量饮食、体力活动不足及增龄是2型糖尿病最主要的环境因素,高血压、血脂异常等因素也会增加患病风险。但是目前,2型糖尿病与大多数心血管疾病的发病之间的关系尚未得到明确的报道。因此,来自英国伦敦大学的Shah教授带领了研究组进行了一项包含了一百九十万人群的队列研究,试图寻找2型糖尿病与12种心血管疾病的初始表现间的关联。该研究结果发表于The Lancet Diabete

Circ Heart Fail:HbA1c水平可以预测T2DM心衰事件发生率

2型糖尿病目前公认的独立于冠状动脉粥样硬化性疾病和高血压病的发生心衰的独立风险因素, 且血糖控制水平会影响心衰发生率。高血糖会加重心肌损伤,同时上调肾素-血管紧张素-醛固酮系统,增加氧化应激。高血糖症也与心肌细胞脂毒性、线粒体功能障碍、钙处理受损等有关,流行病学证据,证明HbA1c与心衰发生风险相关。但是尚无具体的研究来评估T2DM心衰发生率和血糖控制水平之间的关系。最近,来自英国的Helen M

点评:继续寻找2型糖尿病的基因是否有价值?

2型糖尿病是一种高度异质性的疾病,在复杂的基因背景下,营养物质过多摄入导致体内糖脂代谢异常,引起疾病发生。因此,遗传和环境是2型糖尿病发生的两大重要方面。正方Mark McCarthy和反方Mike Lean正是从这两个方面来看待目前关于2型糖尿病的研究。在遗传学方面,正如Mark McCarthy所说,通过GWAS研究和一些表观遗传学的研究从基础研究的角度在一定程度上揭示了基因在2型糖尿病发生中

Baidu
map
Baidu
map
Baidu
map